Maxigesic around the world
New Zealand - OTC Launched Oct 09
CACM- OTC Launched July 18
Nordics - RX - 3 countries
Launched - 19
France - RX Launch pending - 20
Australia - OTC Launched Feb 14
UAE - OTC Launched Jan 15
Israel - OTC Launched Oct 17
Germany - RX Launched - Jly 20
Italy - RX Launched April 15
Ireland - OTC Launched July 18
Spain - OTC Launched April 19
Eastern Europe - OTC Launches pending 20
Belgium/Luxembourg - RX
Launch pending 20
Singapore/Malaysia OTC launched June 18
Also sold in Brunei
Portugal - OTC Launched April 19
Slovenia - OTC Launch pending 20
Working to improve your health
Annual Shareholders Meeting 8 September 2020
Important Notice
This presentation has been prepared by AFT Pharmaceuticals Limited ("AFT"), to provide a general overview of the performance of AFT for the financial year ended 31 March 2020. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. This presentation should be read in conjunction with AFT's annual report, market releases and other periodic and continuous disclosure announcements, which are available atwww.nzx.com andwww.asx.com.au.
All amounts are disclosed in New Zealand dollars (NZ$) unless otherwise indicated. All references to FY20XX appearing in this presentation are to the financial year ending 31 March 20XX, unless otherwise indicated.
This presentation is not a recommendation, offer or invitation to acquire AFT's securities or other form of financial advice or disclosure document. While reasonable care has been taken in compiling this presentation, none of AFT nor its subsidiaries, directors, employees, agents or advisers (to the maximum extent permitted by law) gives any warranty or representation (express or implied) of the accuracy, completeness or reliability of the information contained in it nor takes any responsibility for it. The information in this presentation has not been and will not be independently verified or audited.
ASMSEP2020
This presentation may contain certain forward-looking statements and comments about future events, including with respect to the financial condition, results, operations and business of AFT. These statements are based on management's current expectations, which may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct, and the actual events or results may differ materially and adversely from these statements.
Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon (and is not) an indication of future performance.
CHAIRMAN'S INTRODUCTION
ASMSEP2020
David Flacks
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
AFT Pharmaceuticals Limited published this content on 08 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 September 2020 22:29:01 UTC